



15th JUNE 2020 | Numéro 6

XENOTHERA NEWS

- Special Edition -


Official news bulletin for XAV-19

EDITORIAL

by **Odile DUVAUX**, President of XENOTHERA

It has been a while since we last shared any information via our newsletter, through which we regularly like to update you. Over the past few days, in addition to our daily commitment to developing our anti-Covid treatment, XAV-19, we have been devoting our energy to our search for funding. A little more than 2 months ago, we launched our appeal for contributions, which immediately resulted in a phenomenal response from the general public in a tremendous display of citizen momentum. Today, I am pleased to announce that we have funding of more than 7 million euros, with support from the French government, Bpifrance, the Pays de la Loire Region, Nantes Métropole, the European Union and our shareholders. This funding will allow XENOTHERA to develop XAV-19 and our entire product portfolio.

[Click to hear Odile Duvaux's message in full:](#)



[Find below our last press release:](#)

[XENOTHERA secures funding of more than 7 million euros for its anti-Covid treatment and the acceleration of its product portfolio](#)



MAIN FOCUS

Update on XAV-19 news

The total amount thus collected for the XAV-19 treatment makes it possible to finance a clinical trial involving several hundred patients in a clinical approach supported by discussions with the ANSM, the French agency which ensures safety and regulatory adequacy of all clinical trials taking place in France, and by validation of the protocol by XENOTHERA's clinical and scientific teams. The XAV-19 clinical trial, intended for newly-hospitalized patients to prevent the disease from worsening, will be conducted by several hospitals so that conclusions can be reached quickly. The current level of financing, higher than the initial estimate of 3M €, will also allow XENOTHERA to revise its ambitions upwards, and to optimize the implementation of its treatment by preparing large-scale production of its anti-COVID19 drug; with the aim of maintaining a production rate that can at least supply French needs in the event of a resurgence of the SARS-CoV-2 epidemic, and to establish a rapid reaction system in the event of a new serious viral epidemic.

TESTIMONY

Support of XENOTHERA

In his role as an incubator, Jean-François Balducchi, CEO of the Nantes technopole Atlanpole, has supported XENOTHERA from the beginning. In this video, he explains why the biotech remains one of the cornerstones of the Atlanpole Biotherapies Bio Cluster (one of 6 competitiveness clusters dedicated to health in France), and how it continues to grow and develop its international ambition, while continuing to do a lot of R&D.

[Click on the image to hear his testimony:](#)





In the media

The major milestone for the development of XENOTHERA's anti-Covid treatment, which we are sharing with you this week, also gives us the opportunity to thank the media who have been reporting on our progress since March.

Among the latest in the regional, national and even international press, we would like to highlight in particular the article **published in LES ECHOS Weekend** which highlighted XENOTHERA: **"7 innovateurs révélés par la crise" (7 innovators revealed by the crisis)**. The company is the **only French player out of all the remarkable initiatives cited in the article.**

[Click on the image to access the article](#)
(With thanks to Les Echos for their permission to publish this article in full):



Find our latest press releases:

- [XENOTHERA launches support campaign to finalise treatment for coronavirus infections, including Covid-19](#)
- [LFB signs agreement with biotech XENOTHERA](#)
- [The search for Covid-19 treatments: how can the antibodies developed by the French biotech XENOTHERA help? \(in french\)](#)
- [XENOTHERA secures funding of more than 7 million euros for its anti-Covid treatment and the acceleration of its product portfolio](#)

XENOTHERA :

XENOTHERA, created in 2014, is a Nantes-based biotech company which develops "humanized" polyclonal antibodies. Their technological platform is based on dual expertise in animal genetics and a mastery of immunology. The company has a complete portfolio of products, the first of which, LIS1, an immunosuppressant for transplants, has been in clinical trials since 2019. XENOTHERA is part of the Nantes scientific, medical and academic environment and is supported by the Pays de la Loire region's Atlanpole competitiveness cluster. Since its creation, the company has raised 6 million euros in equity and has received support from the BPI.

For more information go to www.xenothera.com

Follow XENOTHERA on social media :



Contact :

XENOTHERA

1 rue Vauban - 44 000 Nantes
xenothera@izsogood.co